Literature DB >> 26133967

Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram.

B Groot Koerkamp1, J K Wiggers2, M Gonen3, A Doussot4, P J Allen4, M G H Besselink5, L H Blumgart4, O R C Busch5, M I D'Angelica4, R P DeMatteo4, D J Gouma5, T P Kingham4, T M van Gulik5, W R Jarnagin4.   

Abstract

BACKGROUND: The objective of this study was to derive and validate a prognostic nomogram to predict disease-specific survival (DSS) after a curative intent resection of perihilar cholangiocarcinoma (PHC). PATIENTS AND METHODS: A nomogram was developed from 173 patients treated at Memorial Sloan Kettering Cancer Center (MSKCC), New York, USA. The nomogram was externally validated in 133 patients treated at the Academic Medical Center (AMC), Amsterdam, The Netherlands. Prognostic accuracy was assessed with concordance estimates and calibration, and compared with the American Joint Committee on Cancer (AJCC) staging system. The nomogram will be available as web-based calculator at mskcc.org/nomograms.
RESULTS: For all 306 patients, the median overall survival (OS) was 40 months and the median DSS 41 months. Median follow-up for patients alive at last follow-up was 48 months. Lymph node involvement, resection margin status, and tumor differentiation were independent prognostic factors in the derivation cohort (MSKCC). A nomogram with these prognostic factors had a concordance index of 0.73 compared with 0.66 for the AJCC staging system. In the validation cohort (AMC), the concordance index was 0.72, compared with 0.60 for the AJCC staging system. Calibration was good in the derivation cohort; in the validation cohort patients had a better median DSS than predicted by the model.
CONCLUSIONS: The proposed nomogram to predict DSS after curative intent resection of PHC had a better prognostic accuracy than the AJCC staging system. Calibration was suboptimal because DSS differed between the two institutions. The nomogram can inform patients and physicians, guide shared decision making for adjuvant therapy, and stratify patients in future randomized, controlled trials.
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  cholangiocarcinoma; nomogram; prognostic model; survival

Mesh:

Year:  2015        PMID: 26133967      PMCID: PMC4754626          DOI: 10.1093/annonc/mdv279

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  24 in total

Review 1.  Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis.

Authors:  Anne M Horgan; Eitan Amir; Thomas Walter; Jennifer J Knox
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

2.  American Joint Committee on Cancer staging for resected perihilar cholangiocarcinoma: a comparison of the 6th and 7th editions.

Authors:  Bas Groot Koerkamp; Jimme K Wiggers; Peter J Allen; Olivier R C Busch; Michael I D'Angelica; Ronald P DeMatteo; Yuman Fong; Mithat Gonen; Dirk J Gouma; T Peter Kingham; Thomas M van Gulik; William R Jarnagin
Journal:  HPB (Oxford)       Date:  2014-09-29       Impact factor: 3.647

3.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

4.  Nomogram prediction of survival and recurrence in patients with extrahepatic bile duct cancer undergoing curative resection followed by adjuvant chemoradiation therapy.

Authors:  Changhoon Song; Kyubo Kim; Eui Kyu Chie; Jin Ho Kim; Jin-Young Jang; Sun Whe Kim; Sae-Won Han; Do-Youn Oh; Seock-Ah Im; Tae-You Kim; Yung-Jue Bang; Sung W Ha
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-11-01       Impact factor: 7.038

5.  Prevention of implantation metastases after resection of proximal bile duct tumours with pre-operative low dose radiation therapy.

Authors:  M F Gerhards; D G Gonzalez; H ten Hoopen-Neumann; T M van Gulik; L T de Wit; D J Gouma
Journal:  Eur J Surg Oncol       Date:  2000-08       Impact factor: 4.424

6.  Novel prognostic scoring system after surgery for Klatskin tumor.

Authors:  Gernot M Kaiser; Andreas Paul; George Sgourakis; Ernesto P Molmenti; Alexander Dechêne; Tanja Trarbach; Martin Stuschke; Hideo A Baba; Guido Gerken; Georgios C Sotiropoulos
Journal:  Am Surg       Date:  2013-01       Impact factor: 0.688

7.  Assessment of nodal status for perihilar cholangiocarcinoma: location, number, or ratio of involved nodes.

Authors:  Taro Aoba; Tomoki Ebata; Yukihiro Yokoyama; Tsuyoshi Igami; Gen Sugawara; Yu Takahashi; Yuji Nimura; Masato Nagino
Journal:  Ann Surg       Date:  2013-04       Impact factor: 12.969

8.  Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience.

Authors:  Sung Gyu Lee; Gi Won Song; Shin Hwang; Tae Yong Ha; Deok Bog Moon; Dong Hwan Jung; Ki Hun Kim; Chul Soo Ahn; Myung Hwan Kim; Sung Koo Lee; Kyu Bo Sung; Gi Young Ko
Journal:  J Hepatobiliary Pancreat Sci       Date:  2009-10-23       Impact factor: 7.027

9.  Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.

Authors:  Jason S Gold; Mithat Gönen; Antonio Gutiérrez; Javier Martín Broto; Xavier García-del-Muro; Thomas C Smyrk; Robert G Maki; Samuel Singer; Murray F Brennan; Cristina R Antonescu; John H Donohue; Ronald P DeMatteo
Journal:  Lancet Oncol       Date:  2009-09-28       Impact factor: 41.316

10.  Surgical outcomes of 230 resected hilar cholangiocarcinoma in a single centre.

Authors:  Sun Choon Song; Dong Wook Choi; Alfred Wei-Chieh Kow; Seong Ho Choi; Jin Seok Heo; Woo Seok Kim; Min Jung Kim
Journal:  ANZ J Surg       Date:  2012-09-03       Impact factor: 1.872

View more
  34 in total

1.  Emerging local ablative therapies for unresectable perihilar cholangiocarinoma: Time for re-appraisal.

Authors:  Pim B Olthof; Robert J Coelen; Michal Heger; Heinz-Josef Klümpen; Erik A Rauws; Thomas M van Gulik
Journal:  United European Gastroenterol J       Date:  2017-01-12       Impact factor: 4.623

2.  A Comparison of Prognostic Schemes for Perihilar Cholangiocarcinoma.

Authors:  Stefan Buettner; Jeroen L A van Vugt; Faiz Gani; Bas Groot Koerkamp; Georgios Antonios Margonis; Cecilia G Ethun; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Shishir K Maithel; Alfredo Guglielmi; Jan N M IJzermans; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2016-07-13       Impact factor: 3.452

3.  Surgical Site Infection Is Associated with Tumor Recurrence in Patients with Extrahepatic Biliary Malignancies.

Authors:  Stefan Buettner; Cecilia G Ethun; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Matthew Weiss; Ryan C Fields; Bradley Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Bas Groot Koerkamp; Shishir K Maithel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2017-09-14       Impact factor: 3.452

4.  High mortality after ALPPS for perihilar cholangiocarcinoma: case-control analysis including the first series from the international ALPPS registry.

Authors:  Pim B Olthof; Robert J S Coelen; Jimme K Wiggers; Bas Groot Koerkamp; Massimo Malago; Roberto Hernandez-Alejandro; Stefan A Topp; Marco Vivarelli; Luca A Aldrighetti; Ricardo Robles Campos; Karl J Oldhafer; William R Jarnagin; Thomas M van Gulik
Journal:  HPB (Oxford)       Date:  2017-03-06       Impact factor: 3.647

5.  Radial margin status should be determined in resected perihilar cholangiocarcinoma.

Authors:  Roeland F de Wilde; Bas Groot Koerkamp
Journal:  Hepatobiliary Surg Nutr       Date:  2019-10       Impact factor: 7.293

6.  Perioperative blood transfusion is not associated with overall survival or time to recurrence after resection of perihilar cholangiocarcinoma.

Authors:  Annemiek M Dekker; Jimme K Wiggers; Robert J Coelen; Rowan F van Golen; Marc G H Besselink; Olivier R C Busch; Joanne Verheij; Markus W Hollmann; Thomas M van Gulik
Journal:  HPB (Oxford)       Date:  2016-01-06       Impact factor: 3.647

7.  Survival after resection of perihilar cholangiocarcinoma in patients with lymph node metastases.

Authors:  Stefan Buettner; Jeroen L A van Vugt; Marcia P Gaspersz; Robert J S Coelen; Eva Roos; Tim A Labeur; Georgios A Margonis; Cecilia G Ethun; Shishir K Maithel; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley A Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Jan N M IJzermans; Thomas M van Gulik; Timothy M Pawlik; Bas Groot Koerkamp
Journal:  HPB (Oxford)       Date:  2017-05-23       Impact factor: 3.647

8.  Impact of Biliary Drainage on Multidetector-Row Computed Tomography on R0 Resection of Perihilar Cholangiocarcinoma.

Authors:  Isamu Hosokawa; Hiroaki Shimizu; Hideyuki Yoshitomi; Katsunori Furukawa; Tsukasa Takayashiki; Masaru Miyazaki; Masayuki Ohtsuka
Journal:  World J Surg       Date:  2018-11       Impact factor: 3.352

9.  Conditional probability of long-term survival after resection of hilar cholangiocarcinoma.

Authors:  Stefan Buettner; Georgios A Margonis; Yuhree Kim; Faiz Gani; Cecilia G Ethun; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Shishir K Maithel; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2016-04-24       Impact factor: 3.647

10.  Integrating Machine Learning and Tumor Immune Signature to Predict Oncologic Outcomes in Resected Biliary Tract Cancer.

Authors:  Gu-Wei Ji; Ke Wang; Yong-Xiang Xia; Jin-Song Wang; Xue-Hao Wang; Xiang-Cheng Li
Journal:  Ann Surg Oncol       Date:  2020-11-23       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.